EV-100
Broad-spectrum viral infections
Pre-clinicalActive
Key Facts
About Evrys Bio
Evrys Bio is an early-stage biotech pioneering a novel antiviral approach through allosteric modulation of the host protein SIRT2. This strategy aims to create broad-spectrum therapies that are less susceptible to viral resistance by targeting the host's metabolic reprogramming during infection. Led by a seasoned team with strong academic and industry backing, the company is advancing its lead candidate, EV-100, while leveraging significant non-dilutive funding. Its platform holds potential not only for infectious diseases but also for conditions like oncology and neurodegeneration.
View full company profile